Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jos Lommerse

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Pharmacokinetics|October 22, 2024
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric PopulationThijs J Zweers, Jos Lommerse, Eline van Maanen, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 9, 2021
V<sup>2</sup> ACHER: Visualization of complex trial data in pharmacometric analyses with covariatesJos Lommerse, Nele Plock, S Y Amy Cheung, et al.
The AAPS Journal|October 14, 2025
Effective Visualizations Using "vachette" to Assess and Communicate Pharmacometric Model ResultsJos Lommerse, Anna Largajolli, James Craig, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 29, 2019
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110Diana F Clarke, Mark Mirochnick, Edward P Acosta, et al.
Communications Medicine|April 16, 2025
Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus diseaseNele Plock, Jeffrey R Sachs, Xiaowei Zang, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 20, 2019
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal DosingJos Lommerse, Diana Clarke, Thomas Kerbusch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2020
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)Diana F Clarke, Edward P Acosta, Mae Cababasay, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2020
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097Diana F Clarke, Jos Lommerse, Edward P Acosta, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the seriesArthur Oubrie, Allard Kaptein, Edwin de Zwart, et al.
Ebiomedicine|November 14, 2021
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxisBrian M Maas, Jos Lommerse, Nele Plock, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Pharmacokinetics|October 22, 2024
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric PopulationThijs J Zweers, Jos Lommerse, Eline van Maanen, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 9, 2021
V<sup>2</sup> ACHER: Visualization of complex trial data in pharmacometric analyses with covariatesJos Lommerse, Nele Plock, S Y Amy Cheung, et al.
The AAPS Journal|October 14, 2025
Effective Visualizations Using "vachette" to Assess and Communicate Pharmacometric Model ResultsJos Lommerse, Anna Largajolli, James Craig, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 29, 2019
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110Diana F Clarke, Mark Mirochnick, Edward P Acosta, et al.
Communications Medicine|April 16, 2025
Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus diseaseNele Plock, Jeffrey R Sachs, Xiaowei Zang, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 20, 2019
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal DosingJos Lommerse, Diana Clarke, Thomas Kerbusch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2020
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)Diana F Clarke, Edward P Acosta, Mae Cababasay, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2020
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097Diana F Clarke, Jos Lommerse, Edward P Acosta, et al.
Bioorganic & Medicinal Chemistry Letters|November 29, 2011
Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the seriesArthur Oubrie, Allard Kaptein, Edwin de Zwart, et al.
Ebiomedicine|November 14, 2021
Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxisBrian M Maas, Jos Lommerse, Nele Plock, et al.
Pageof 1